Insider Transactions in Q3 2021 at Horizon Therapeutics Public LTD CO (HZNP)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2021
|
Timothy P Walbert Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-2.7%
|
$5,500,000
$110.92 P/Share
|
|
Sep 21
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
46,271
-83.54%
|
$5,089,810
$110.0 P/Share
|
|
Sep 21
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,271
+45.52%
|
$323,897
$7.61 P/Share
|
|
Sep 17
2021
|
Timothy P Walbert Chairman, President and CEO |
BUY
Bona fide gift
|
Indirect |
218,241
+47.83%
|
-
|
|
Sep 17
2021
|
Timothy P Walbert Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
218,241
-13.82%
|
-
|
|
Sep 17
2021
|
Brian K Beeler EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
28,143
-30.95%
|
$3,011,301
$107.91 P/Share
|
|
Sep 09
2021
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
23,250
-25.45%
|
$2,511,000
$108.05 P/Share
|
|
Sep 09
2021
|
Andy Pasternak EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+33.28%
|
$674,250
$29.52 P/Share
|
|
Sep 03
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
BUY
Bona fide gift
|
Indirect |
4,042
+12.99%
|
-
|
|
Sep 03
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
4,042
-30.72%
|
-
|
|
Aug 27
2021
|
Timothy P Walbert Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,435
+0.87%
|
$163,570
$22.14 P/Share
|
|
Aug 25
2021
|
Paul W. Hoelscher EVP, CFO |
BUY
Bona fide gift
|
Indirect |
6,163
+3.34%
|
-
|
|
Aug 25
2021
|
Paul W. Hoelscher EVP, CFO |
SELL
Bona fide gift
|
Direct |
6,163
-74.6%
|
-
|
|
Aug 16
2021
|
Brian K Beeler EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
74,898
-45.17%
|
$7,939,188
$106.0 P/Share
|
|
Aug 16
2021
|
Brian K Beeler EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
65,857
+28.43%
|
$1,448,854
$22.14 P/Share
|
|
Aug 05
2021
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Open market or private sale
|
Direct |
7,542
-34.71%
|
$799,452
$106.34 P/Share
|
|
Jul 30
2021
|
Timothy P Walbert Chairman, President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.45%
|
$2,550,000
$102.11 P/Share
|
|
Jul 28
2021
|
Brian K Beeler EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,573
-2.51%
|
$262,446
$102.5 P/Share
|
|
Jul 28
2021
|
Brian K Beeler EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,806
+5.36%
|
-
|
|
Jul 28
2021
|
Michael A. Des Jardin EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
3,599
-3.81%
|
$367,098
$102.5 P/Share
|
|
Jul 28
2021
|
Michael A. Des Jardin EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
7,257
+7.13%
|
-
|
|
Jul 28
2021
|
Paul W. Hoelscher EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,858
-31.83%
|
$393,516
$102.5 P/Share
|
|
Jul 28
2021
|
Paul W. Hoelscher EVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
8,708
+41.81%
|
-
|
|
Jul 28
2021
|
Barry Moze EVP, Chief Admin. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,215
-4.08%
|
$327,930
$102.5 P/Share
|
|
Jul 28
2021
|
Barry Moze EVP, Chief Admin. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,257
+8.42%
|
-
|
|
Jul 28
2021
|
Andy Pasternak EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,858
-14.18%
|
$393,516
$102.5 P/Share
|
|
Jul 28
2021
|
Andy Pasternak EVP, Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,708
+24.24%
|
-
|
|
Jul 28
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,215
-19.64%
|
$327,930
$102.5 P/Share
|
|
Jul 28
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,257
+30.71%
|
-
|
|
Jul 28
2021
|
Timothy P Walbert Chairman, President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,432
-1.75%
|
$1,574,064
$102.5 P/Share
|
|
Jul 28
2021
|
Timothy P Walbert Chairman, President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
34,833
+3.8%
|
-
|
|
Jul 22
2021
|
Michael G Grey Director |
SELL
Open market or private sale
|
Direct |
5,000
-60.0%
|
$500,000
$100.03 P/Share
|
|
Jul 22
2021
|
Michael G Grey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.37 P/Share
|
|
Jul 08
2021
|
Timothy P Walbert Chairman, President and CEO |
SELL
Bona fide gift
|
Direct |
5,000
-0.59%
|
-
|
|
Jul 08
2021
|
Barry Moze EVP, Chief Admin. Officer |
SELL
Open market or private sale
|
Direct |
35,076
-12.36%
|
$3,226,992
$92.37 P/Share
|
|
Jul 01
2021
|
Elizabeth H.Z. Thompson EVP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,988
-21.6%
|
$574,848
$96.59 P/Share
|
|
Jul 01
2021
|
Elizabeth H.Z. Thompson EVP, Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
12,077
+30.35%
|
-
|
|
Jul 01
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
54,789
-29.84%
|
$5,204,955
$95.0 P/Share
|
|
Jul 01
2021
|
Jeffrey W Sherman EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,287
-36.71%
|
$502,265
$95.0 P/Share
|